Caplacizumab and Immunosuppressive Therapy Without Firstline Therapeutic Plasma Exchange in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura

NCT05468320 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

51

Enrollment

INDUSTRY

Sponsor class

Conditions

Thrombotic Thrombocytopenic Purpura

Interventions

DRUG: Caplacizumab
DRUG: Corticosteroids
BIOLOGICAL: anti-CD20 antibody

Sponsor

Sanofi